Biopharma and med-tech companies raising money in public or private financings, including: Arcadia, Adial, Azora, Enliven, Human Continuum, Parabilis, Regeneron.
Biopharma and med-tech companies raising money in public or private financings, including: Atossa, Cequr, Edesa, Humacyte, Ideaya, Kardigan, Nyxoah, Thruflo.
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone receptor, at the Endocrine Society’s 2026 annual meeting on June 15.
Biopharma and med-tech companies raising money in public or private financings, including: Aim Immunotech, Antogen, Cerus, City, Corvus, Dicot, Eloxx, Ideaya, Idorsia, Shattuck, Starton.
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed it. The oncology-focused firm priced its upsized IPO of 3.5 million shares at $20 apiece for gross proceeds of $670 million, an amount that could rise to $770 million should underwriters exercise their full 5-million-share overallotment option.
Total biopharma financing through the first five months of 2026 reached $49.46 billion, the third-highest total for the period in the dataset and more than doubling of 2025’s $21.4 billion over the same stretch.
RSS
